Clicky

Biora Therapeutics, Inc.(BIOR)

Description: Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.


Keywords: Biotechnology Biology Disease Drug Delivery Genomics In Vitro Systems Science Precision Medicine Proteomics Systems Biology Epigenomics Metabolomics

Home Page: www.bioratherapeutics.com

BIOR Technical Analysis

4330 La Jolla Village Drive
San Diego, CA 92122
United States
Phone: 855 293 2639


Officers

Name Title
Mr. Aditya P. Mohanty M.B.A. CEO & Director
Mr. Eric d'Esparbes Chief Financial Officer
Mr. Clarke Neumann J.D. Gen. Counsel & Sec.
Eric Fox VP of Fin. & Accounting & Treasurer
Mr. Troy Seelye Chief Information Officer
Mr. George Gianakopoulos Sr. VP of Sales
Ms. Robyn Hatton Head of HR
Mr. Kevin Howe Ph.D. Sr. VP of Strategic Operations
Dr. Sharat Singh Ph.D. Head of Research
Dr. Paul Shabram M.B.A. Head of Technical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 53.7639
IPO Date: 2020-06-19
Fiscal Year End: December
Full Time Employees: 124
Back to stocks